Relapsed Hematologic Malignancy Clinical Trials in Seattle, Washington
2 recruitingSeattle, Washington
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Not Applicable
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Multiple MyelomaRelapsed Hematologic Malignancy
Pack Health100 enrolled1 locationNCT05956457